| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jitschak G Storosum, André J A Elferink, Barbara J van Zwieten, Roel van Strik, Witte J G Hoogendijk, André W Broekman. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophrenia bulletin. vol 28. issue 2. 2003-05-01. PMID:12693427. |
in this article we report on a meta-analysis of the published studies of amisulpride conducted in order to demonstrate efficacy on primary negative symptoms in schizophrenia. |
2003-05-01 |
2023-08-12 |
Not clear |
| Matthias J Müller, Hermann Wetzel, Franz-Xaver Eich, Werner Rein, Alain Puech, Otto Benker. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. Journal of clinical psychopharmacology. vol 22. issue 6. 2003-03-31. PMID:12454554. |
dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. |
2003-03-31 |
2023-08-12 |
Not clear |
| Stephen Martin, Henri Lĵo, Joseph Peuskens, Srinivasa Thirumalai, Agnes Giudicelli, Odile Fleurot, Werner Rei. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Current medical research and opinion. vol 18. issue 6. 2003-03-20. PMID:12442883. |
a double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. |
2003-03-20 |
2023-08-12 |
Not clear |
| Stephen Martin, Henri Lĵo, Joseph Peuskens, Srinivasa Thirumalai, Agnes Giudicelli, Odile Fleurot, Werner Rei. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Current medical research and opinion. vol 18. issue 6. 2003-03-20. PMID:12442883. |
to compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia. |
2003-03-20 |
2023-08-12 |
Not clear |
| L Pan. Clinical implications of dopamine research in schizophrenia. Current medical research and opinion. vol 18 Suppl 3. 2003-02-06. PMID:12418605. |
amisulpride is a substituted benzamide antipsychotic, which is known to be efficacious against both the positive and the negative symptoms of schizophrenia and to have a lower propensity to induce eps than conventional antipsychotics. |
2003-02-06 |
2023-08-12 |
Not clear |
| Daniel Sechter, Joseph Peuskens, Odile Fleurot, Werner Rein, Yves Lecrubie. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 6. 2003-01-24. PMID:12464464. |
amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. |
2003-01-24 |
2023-08-12 |
Not clear |
| Daniel Sechter, Joseph Peuskens, Odile Fleurot, Werner Rein, Yves Lecrubie. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 6. 2003-01-24. PMID:12464464. |
this multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (dsm iv) with a recent worsening of symptoms. |
2003-01-24 |
2023-08-12 |
Not clear |
| P Rosenzweig, M Canal, A Patat, L Bergougnan, I Zieleniuk, G Bianchett. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human psychopharmacology. vol 17. issue 1. 2003-01-13. PMID:12404702. |
amisulpride is clinically effective on the negative symptoms of acute schizophrenia exacerbations at low dosages (50-300 mg/day), and also on the positive symptoms of the disease at high dosages (400-800 mg/day). |
2003-01-13 |
2023-08-12 |
human |
| M J Müller, H Wetzel, O Benker. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. International clinical psychopharmacology. vol 17. issue 5. 2002-12-03. PMID:12177587. |
differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. |
2002-12-03 |
2023-08-12 |
Not clear |
| J Peuskens, H J Möller, A Puec. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 12. issue 4. 2002-11-15. PMID:12126869. |
amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. |
2002-11-15 |
2023-08-12 |
Not clear |
| J Peuskens, H J Möller, A Puec. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 12. issue 4. 2002-11-15. PMID:12126869. |
the brief psychiatric rating scale (bprs) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia. |
2002-11-15 |
2023-08-12 |
Not clear |
| Guillaume Vaiva, Pierre Thomas, Pierre Michel Llorca, Sylvie Dupont, Olivier Cottencin, Patrick Devos, Olivier Mazas, Claire Rascle, Marc Steinling, Michel Goudeman. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry research. vol 115. issue 1-2. 2002-10-29. PMID:12165366. |
both efficacy and a relatively low rate of side effects of low-dose amisulpride in the deficit forms of schizophrenia were found as expected from earlier placebo-controlled studies. |
2002-10-29 |
2023-08-12 |
Not clear |
| Gary Remington, Shitij Kapu. Review: amisulpride is effective and safe for schizophrenia. Evidence-based mental health. vol 5. issue 3. 2002-08-15. PMID:12180452. |
review: amisulpride is effective and safe for schizophrenia. |
2002-08-15 |
2023-08-12 |
Not clear |
| N E Mota, M S Lima, B G Soare. Amisulpride for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2002-08-09. PMID:12076408. |
amisulpride for schizophrenia. |
2002-08-09 |
2023-08-12 |
Not clear |
| N E Mota, M S Lima, B G Soare. Amisulpride for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2002-08-09. PMID:12076408. |
amisulpride is said to be an "atypical" antipsychotic which induces less movement disorder and which is effective for the negative symptoms of schizophrenia. |
2002-08-09 |
2023-08-12 |
Not clear |
| H J Mölle. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. European archives of psychiatry and clinical neuroscience. vol 251. issue 5. 2002-07-09. PMID:11829208. |
amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. |
2002-07-09 |
2023-08-12 |
Not clear |
| H J Mölle. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. European archives of psychiatry and clinical neuroscience. vol 251. issue 5. 2002-07-09. PMID:11829208. |
amisulpride is a dopamine d2/d3-selective antipsychotic drug with potent antipsychotic efficacy in acute exacerbations of schizophrenia. |
2002-07-09 |
2023-08-12 |
Not clear |
| T Burns, R Bal. Clinical advantages of amisulpride in the treatment of acute schizophrenia. The Journal of international medical research. vol 29. issue 6. 2002-06-25. PMID:11803729. |
clinical advantages of amisulpride in the treatment of acute schizophrenia. |
2002-06-25 |
2023-08-12 |
Not clear |
| T Burns, R Bal. Clinical advantages of amisulpride in the treatment of acute schizophrenia. The Journal of international medical research. vol 29. issue 6. 2002-06-25. PMID:11803729. |
five studies have been conducted with the atypical anti-psychotic amisulpride (100-1200 mg/day) involving 1358 patients with acute exacerbations of schizophrenia; four studies were short-term (4-8 weeks), double-blind studies and one was a 12-month, open, randomized comparison. |
2002-06-25 |
2023-08-12 |
Not clear |
| Monique P Curran, Caroline M Perr. Spotlight on amisulpride in schizophrenia. CNS drugs. vol 16. issue 3. 2002-05-03. PMID:11888341. |
spotlight on amisulpride in schizophrenia. |
2002-05-03 |
2023-08-12 |
Not clear |